Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Exploration of Potential Relationships between CD22 and Selected Safety Outcomes in the Inotuzumab Ozogamicin Phase 3 INO-VATE Study

Partow Kebriaei, MD, Daniel J. DeAngelo, MD, Anjali S. Advani, MD, Susan M. O'Brien, MD, David Marks, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Tao Wang, Erik Vandendries, MD PhD, A. Douglas Laird, PhD, Sonja Nick, MSc, Matthias Stelljes, MD

Blood (2018) 132 (Supplement 1): 4031.

https://doi.org/10.1182/blood-2018-99-110552

Published: 2018

Journal Articles

Comparison of CD22 Expression between Baseline, End of Treatment, and Relapse Among Patients Treated with Inotuzumab Ozogamicin Who Responded and Subsequently Relapsed in Two Clinical Trials

Hagop M. Kantarjian, MD, Wendy Stock, MD, Ryan D. Cassaday, MD, Daniel J. DeAngelo, MD, Elias J. Jabbour, MD, Susan M. O'Brien, MD, Matthias Stelljes, MD, Tao Wang, Katherine F Liau, Kevin Nguyen, Barbara Sleight, Erik Vandendries, MD PhD, Alexander Neuhof, MD, A. Douglas Laird, Anjali S. Advani, MD

Blood (2018) 132 (Supplement 1): 2699.

https://doi.org/10.1182/blood-2018-99-110826

Published: 2018

Journal Articles

Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Global Phase 3 INO-VATE Trial: Efficacy and Safety By Baseline CD22 Expression Level

Hagop M. Kantarjian, MD, Wendy Stock, MD, Ryan D. Cassaday, MD, Daniel J. DeAngelo, MD, Elias J. Jabbour, MD, Susan M. O'Brien, MD, Matthias Stelljes, MD, Tao Wang, PhD, Luisa Paccagnella, Kevin Nguyen, Barbara Sleight, Erik Vandendries, MD PhD, A. Douglas Laird, Anjali S. Advani, MD

Blood (2017) 130 (Supplement 1): 1272.

https://doi.org/10.1182/blood.V130.Suppl_1.1272.1272

Published: 2017

Journal Articles

Inotuzumab Ozogamicin (InO) Vs Standard of Care (SC) in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Long-Term Results of the Phase 3 INO-VATE Study

Hagop M. Kantarjian, MD, Daniel J. DeAngelo, MD, Matthias Stelljes, MD, Michaela Liedtke, MD, Wendy Stock, MD, Nicola Goekbuget, MD, Susan M. O'Brien, MD, Elias J. Jabbour, MD, Tao Wang, PhD, Jane Liang White, ScD, Barbara Sleight, Erik Vandendries, MD PhD, Anjali S. Advani, MD

Blood (2017) 130 (Supplement 1): 2574.

https://doi.org/10.1182/blood.V130.Suppl_1.2574.2574

Published: 2017

Journal Articles

Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin (INO) for Relapsed / Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Partow Kebriaei, MD, Matthias Stelljes, MD, Daniel J. DeAngelo, MD, Nicola Goekbuget, MD, Hagop M. Kantarjian, MD, Anjali S. Advani, MD, Akil Merchant, MD, Wendy Stock, MD, Tao Wang, PhD, Hui Zhang, Fausto Loberiza, Erik Vandendries, MD PhD, David Marks

Blood (2017) 130 (Supplement 1): 886.

https://doi.org/10.1182/blood.V130.Suppl_1.886.886

Published: 2017

Journal Articles

Inotuzumab Ozogamicin (InO) for Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the Global Phase 3 INO-VATE Trial: Efficacy By MLL Status

Anjali S. Advani, MD, Elias J. Jabbour, MD, Matthias Stelljes, MD, Wendy Stock, MD, Michaela Liedtke, MD, Nicola Goekbuget, MD, Susan M. O'Brien, MD, Jane Liang White, ScD, Tao Wang, PhD, A. Douglas Laird, PhD, Erik Vandendries, MD PhD, Hagop M. Kantarjian, MD

Blood (2017) 130 (Supplement 1): 2557.

https://doi.org/10.1182/blood.V130.Suppl_1.2557.2557

Published: 2017

Journal Articles

Indirect Treatment Comparison (ITC) of Inotuzumab Ozogamicin (InO) and Blinatumomab (Blina) for Relapsed or Refractory (RR) Acute Lymphoblastic Leukemia (ALL)

Matthias Stelljes, MD, Yun Su, MD MPH, MS, Kyle Fahrbach, PhD, Erik Vandendries, MD PhD, Veronique Page, M.Sc, Uchenna Onyekwere, MD MPh, Yunyang Wang, M.Sc, M.Pharm, Joseph C. Cappelleri, PhD MPH, MS, Irina Proskorovsky, M.Sc

Blood (2017) 130 (Supplement 1): 2558.

https://doi.org/10.1182/blood.V130.Suppl_1.2558.2558

Published: 2017

Journal Articles

Inotuzumab Ozogamicin Versus Standard of Care for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Phase 3 Randomized INO-Vate Trial: Outcomes By Salvage Treatment Phase

Anjali S. Advani, MD, Elias J. Jabbour, MD, Matthias Stelljes, Daniel J. DeAngelo, MD PhD, Michaela Liedtke, MD, Wendy Stock, MD, Nicola Gökbuget, MD, Susan O'Brien, MD, Kongming Wang, PhD, Tao Wang, PhD, M. Luisa Paccagnella, PhD, Barbara Sleight, MD, Erik Vandendries, MD PhD, Hagop M. Kantarjian, MD

Blood (2016) 128 (22): 5188.

https://doi.org/10.1182/blood.V128.22.5188.5188

Published: 2016

NARROW

Exploration of Potential Relationships between CD22 and Selected Safety Outcomes in the Inotuzumab Ozogamicin Phase 3 INO-VATE Study

Comparison of CD22 Expression between Baseline, End of Treatment, and Relapse Among Patients Treated with Inotuzumab Ozogamicin Who Responded and Subsequently Relapsed in Two Clinical Trials

Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Global Phase 3 INO-VATE Trial: Efficacy and Safety By Baseline CD22 Expression Level

Inotuzumab Ozogamicin (InO) Vs Standard of Care (SC) in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Long-Term Results of the Phase 3 INO-VATE Study

Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin (INO) for Relapsed / Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Inotuzumab Ozogamicin (InO) for Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the Global Phase 3 INO-VATE Trial: Efficacy By MLL Status

Indirect Treatment Comparison (ITC) of Inotuzumab Ozogamicin (InO) and Blinatumomab (Blina) for Relapsed or Refractory (RR) Acute Lymphoblastic Leukemia (ALL)

Inotuzumab Ozogamicin Versus Standard of Care for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Phase 3 Randomized INO-Vate Trial: Outcomes By Salvage Treatment Phase

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only